Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates.
Le Hingrat Q, Collin G, Bachelard A, Ghosn J, Chalal S, Pacanowski J, Peytavin G, Weinheimer S, Marsolais C, Damond F, Matheron S, Charpentier C, Descamps D; ANRS CO5 HIV-2 cohort.
Le Hingrat Q, et al. Among authors: bachelard a.
AIDS. 2022 Jul 1;36(8):1055-1060. doi: 10.1097/QAD.0000000000003218. Epub 2022 Mar 7.
AIDS. 2022.
PMID: 35262531